Loading
Every dated change on the records linked to Metastatic triple-negative breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.
A milestone in how this cancer is treated.
FDA reports 558 randomized patients with previously untreated unresectable locally advanced or metastatic TNBC who were not candidates for PD-1/PD-L1 therapy.
FDA reports 443 randomized patients with previously untreated advanced TNBC and PD-L1 CPS at least 10.
TROPION-Breast02 randomized 644 patients (323/321) with previously untreated advanced TNBC for whom PD-1/PD-L1 inhibitor therapy was unsuitable.
A milestone in how this cancer is treated.
OS 12.
PFS 14.
PFS HR 0.
OS HR 0.
PFS 5.
A milestone in how this cancer is treated.
PFS 8.
PFS HR 0.
No superiority of carboplatin over docetaxel in unselected triple-negative disease; higher response to carboplatin in the germline BRCA1/2 subgroup (Nature Medicine 2018).
A milestone in how this cancer is treated.